ClinicalTrials.gg
WithdrawnNCT04495010CheckMate 7UAUpdated Mar 19, 2021

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

A Phase 2 interventional study of Nivolumab and Ipilimumab in Melanoma, sponsored by Bristol-Myers Squibb. Withdrawn at 118 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
132nd of 142
0 · median 50
Started
2021
with 9 others
Phase 2
76 of 142
18 open now
Registered
86th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 132nd largest by enrollment, is one of 10 that started in 2021, is one of 76 in phase 2, and was the 86th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the role of neoadjuvant immunotherapy and to demonstrate high pathologic complete response (pCR) and near pCR rates in melanoma participants with clinically detectable nodal disease and a high risk of recurrence. Neoadjuvant immunotherapy aims to enhance the systemic T-cell response to tumor antigens while detectable tumor is still present, inducing a stronger and broader tumor-specific immune response. Of the neoadjuvant approaches studied within melanoma, the neoadjuvant combination of nivolumab and ipilimumab has demonstrated high pCR and near pCR rates that may translate to prolonged clinical benefit.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Males and females, ≥ 12 years of age [Except: where local regulations and/or institutional policies do not allow for participants \< 18 years of age (adolescent population) to participate. For those sites, the eligible participant population is 18 years of age or local age of majority, inclusive]
  • Diagnosed with or histologically confirmed Stage IIIB, IIIC, or IIID cutaneous melanoma as per American Joint Committee on Cancer (AJCC) staging system, with ≥ 1 clinically detectable lymph node (N1b, N2b, N3b), which are measurable according to version 1.1 (RECIST 1.1)
  • Adult participants and adolescents 16 to 18 years old must have an (ECOG) scale performance status of 0 or 1. Adolescents \< 16 years old must have Lanksky Play-Performance Status scale performance of ≥ 60
  • Must be treatment-naïve (ie, no prior systemic anticancer therapy as therapy for melanoma or unresectable/metastatic melanoma)
  • Women and men must agree to follow specific methods of , if applicable, while participating in the trial

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding
  • Patients with serious or uncontrolled medical disorders
  • Prior treatment with an anti-programmed cell death protein 1 (), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Neoadjuvant treatment + Adjuvant treatment

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Adjuvant treatment

    Biological: Nivolumab

  • Experimental
    Neo treat with patho response-driven Adju treat or observation

    Neoadjuvant treatment with pathologic response-driven Adjuvant treatment or observation

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    Time frame: Up to 4 years

Secondary outcomes

  1. Recurrence-free survival (RFS) Time from Surgery

    Time frame: Up to 5 years

  2. RFS Time from Adjuvant Therapy

    Time frame: Up to 5 years

  3. Pathologic response rate (pRR) by immune-related pathologic response (irPR)

    Time frame: Up to 5 years

  4. Concordance major pathologic response (MPR) by local and central pathology Review

    MPR is defined as participants achieving either pathologic complete response (pCR) or near pCR

    Time frame: Up to 5 years

  5. RFS by MPR

    Time frame: Up to 5 years

  6. Incidence of Adverse Events (AEs)

    Time frame: Up to 5 years

  7. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 5 years

  8. Incidence of deaths

    Time frame: Up to 5 years

  9. Incidence of clinically significant changes in clinical laboratory results: Hematology tests

    Time frame: Up to 5 years

  10. Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests

    Time frame: Up to 5 years

  11. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

    Time frame: Up to 5 years

  12. Change from baseline in Health-related quality of life (HRQoL) by the Trial Outcome Index (TOI) and Melanoma Subscale (MS)

    Time frame: Up to 5 years

07

Study locations

118 sites
  • Local Institution
    Gilbert, Arizona 85234, United States
  • Local Institution
    Tucson, Arizona 85724, United States
  • Local Institution
    San Francisco, California 94158, United States
  • Local Institution
    Aurora, Colorado 80045, United States
  • Local Institution
    Tampa, Florida 33612, United States
  • Local Institution
    Atlanta, Georgia 30322, United States
  • Local Institution
    Atlanta, Georgia 30342, United States
  • Local Institution
    Marietta, Georgia 30060, United States
  • Local Institution
    Annapolis, Maryland 21401, United States
  • Local Institution
    Boston, Massachusetts 02114, United States
  • Local Institution
    Boston, Massachusetts 02215, United States
  • Local Institution
    Minneapolis, Minnesota 55407, United States
  • Local Institution
    Minneapolis, Minnesota 55455, United States
  • Local Institution
    Hattiesburg, Mississippi 39401, United States
  • Local Institution
    Saint Louis, Missouri 63110, United States
  • Local Institution
    Morristown, New Jersey 07960, United States
  • Local Institution
    New Brunswick, New Jersey 08901, United States
  • Local Institution
    Cleveland, Ohio 44195, United States
  • Local Institution
    Portland, Oregon 97239, United States
  • Local Institution
    Houston, Texas 77030, United States
  • Local Institution
    Salt Lake City, Utah 84112, United States
  • Local Institution
    Charlottesville, Virginia 22908, United States
  • Local Institution
    Seattle, Washington 98109, United States
  • Local Institution
    North Sydney, New South Wales 2060, Australia
  • Local Institution
    Westmead, New South Wales 2145, Australia
  • Local Institution
    Greenslopes, Queensland 4120, Australia
  • Local Institution
    Woolloongabba, Queensland 4120, Australia
  • Local Institution
    Adelaide, South Australia 5000, Australia
  • Local Institution
    Hobart, Tasmania 7000, Australia
  • Local Institution
    Ballarat, Victoria 3350, Australia
  • Local Institution
    Melbourne, Victoria 3000, Australia
  • Local Institution
    Melbourne, Victoria 3004, Australia
  • Local Institution
    Doubleview, Western Australia 6018, Australia
  • Local Institution
    Nedlands, Western Australia 6009, Australia
  • Local Institution
    Graz, 803 6, Austria
  • Local Institution
    Innsbruck, 6020, Austria
  • Local Institution
    Salzburg, 5020, Austria
  • Local Institution
    St. Poelten, 3100, Austria
  • Local Institution
    Wien, A-1090, Austria
  • Local Institution
    Brussels, 1200, Belgium
  • Local Institution
    Gent, 9000, Belgium
  • Local Institution
    Wilrijk, 2610, Belgium
  • Local Institution
    Fortaleza, Ceara 60135237, Brazil
  • Local Institution
    Brasilia, Distrito Federal 70200-730, Brazil
  • Local Institution
    Curitiba, Parana 80530-010, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90035-903, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90050-170, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 91350-200, Brazil
  • Local Institution
    Florianopolis, Santa Catarina 88034-000, Brazil
  • Local Institution
    Sao Jose do Rio Preto, SAO Paulo 15092-415, Brazil
  • Local Institution
    Rio De Janeiro, 20220-410, Brazil
  • Local Institution
    Sao Paulo, 01246-000, Brazil
  • Local Institution
    Sao Paulo, 05308-020, Brazil
  • Local Institution
    Aarhus, 8200, Denmark
  • Local Institution
    Herlev, 2730, Denmark
  • Local Institution
    Odense C, 2000, Denmark
  • Local Institution
    Bordeaux, 33075, France
  • Local Institution
    Dijon, 21079, France
  • Local Institution
    Lille, 59000, France
  • Local Institution
    Marseille, 13385, France
  • Local Institution
    Nantes, 44093, France
  • Local Institution
    Nice, 6200, France
  • Local Institution
    Paris, 75010, France
  • Local Institution
    Pierre-Benite, 69495, France
  • Local Institution
    Rennes, 35000, France
  • Local Institution
    Sr Priest En Jarez, 42270, France
  • Local Institution
    Toulouse, 31059, France
  • Local Institution
    Villejuif, 94800, France
  • Local Institution
    Berlin, 10117, Germany
  • Local Institution
    Erlangen, 91054, Germany
  • Local Institution
    Essen, 45122, Germany
  • Local Institution
    Hannover, 30625, Germany
  • Local Institution
    Heidelberg, 69120, Germany
  • Local Institution
    Kiel, 24105, Germany
  • Local Institution
    Luebeck, 23538, Germany
  • Local Institution
    Mainz, 55131, Germany
  • Local Institution
    Regensburg, 93053, Germany
  • Local Institution
    Tuebingen, 72076, Germany
  • Local Institution
    Wuerzburg, 97080, Germany
  • Local Institution
    Bergamo, 24127, Italy
  • Local Institution
    Meldola, 47014, Italy
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Novara, 28100, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    Pavia, 27100, Italy
  • Local Institution
    Amsterdam, 1066CX, Netherlands
  • Local Institution
    Amsterdam, 1081 HV, Netherlands
  • Local Institution
    Breda, 4818 CK, Netherlands
  • Local Institution
    Geleen, 6162bg, Netherlands
  • Local Institution
    Leiden, 2333 ZA, Netherlands
  • Local Institution
    Rotterdam, 3075 EA, Netherlands
  • Local Institution
    Utrecht, 3584CX, Netherlands
  • Local Institution
    Krakow, 31-115, Poland
  • Local Institution
    Warszawa, 02-781, Poland
  • Local Institution
    Wroclaw, 53-413, Poland
  • Local Institution
    Krasnodar, 350000, Russian Federation
  • Local Institution
    Ryazan, 390011, Russian Federation
  • Local Institution
    Saint Petersburg, 197758, Russian Federation
  • Local Institution
    Saint-Petersburg, 198255, Russian Federation
  • Local Institution
    Barcelona, 08036, Spain

Showing the first 100 of 118 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2021; primary completion for Feb 2024, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Jul 31, 2020
StartEst.
Mar 31, 2021
Primary completionEst.
Feb 28, 2024
CompletionEst.
Oct 23, 2027
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04495010
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Mar 31, 2021 (estimated)
Primary completion
Feb 28, 2024 (estimated)
Completion
Oct 23, 2027 (estimated)
Last update
Mar 19, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion